Targeting phosphoinositide 3-kinase: moving towards therapy
- PMID: 17997386
- DOI: 10.1016/j.bbapap.2007.10.003
Targeting phosphoinositide 3-kinase: moving towards therapy
Abstract
Phosphoinositide 3-kinases (PI3K) orchestrate cell responses including mitogenic signaling, cell survival and growth, metabolic control, vesicular trafficking, degranulation, cytoskeletal rearrangement and migration. Deregulation of the PI3K pathway occurs by activating mutations in growth factor receptors or the PIK3CA locus coding for PI3Kalpha, by loss of function of the lipid phosphatase and tensin homolog deleted in chromosome ten (PTEN/MMAC/TEP1), by the up-regulation of protein kinase B (PKB/Akt), or the impairment of the tuberous sclerosis complex (TSC1/2). All these events are linked to growth and proliferation, and have thus prompted a significant interest in the pharmaceutical targeting of the PI3K pathway in cancer. Genetic targeting of PI3Kgamma (p110gamma) and PI3Kdelta (p110delta) in mice has underlined a central role of these PI3K isoforms in inflammation and allergy, as they modulate chemotaxis of leukocytes and degranulation in mast cells. Proof-of-concept molecules selective for PI3Kgamma have already successfully alleviated disease progress in murine models of rheumatoid arthritis and lupus erythematosus. As targeting PI3K moves forward to therapy of chronic, non-fatal disease, safety concerns for PI3K inhibitors increase. Many of the present inhibitor series interfere with target of rapamycin (TOR), DNA-dependent protein kinase (DNA-PK(cs)) and activity of the ataxia telangiectasia mutated gene product (ATM). Here we review the current disease-relevant knowledge for isoform-specific PI3K function in the above mentioned diseases, and review the progress of >400 recent patents covering pharmaceutical targeting of PI3K. Currently, several drugs targeting the PI3K pathway have entered clinical trials (phase I) for solid tumors and suppression of tissue damage after myocardial infarction (phases I,II).
Similar articles
-
PI3K/PTEN signaling in tumorigenesis and angiogenesis.Biochim Biophys Acta. 2008 Jan;1784(1):150-8. doi: 10.1016/j.bbapap.2007.09.008. Epub 2007 Sep 29. Biochim Biophys Acta. 2008. PMID: 17964232 Review.
-
Reconstitution of the mammalian PI3K/PTEN/Akt pathway in yeast.Biochem J. 2005 Sep 1;390(Pt 2):613-23. doi: 10.1042/BJ20050574. Biochem J. 2005. PMID: 15913452 Free PMC article.
-
New insights into Notch1 regulation of the PI3K-AKT-mTOR1 signaling axis: targeted therapy of γ-secretase inhibitor resistant T-cell acute lymphoblastic leukemia.Cell Signal. 2014 Jan;26(1):149-61. doi: 10.1016/j.cellsig.2013.09.021. Epub 2013 Oct 16. Cell Signal. 2014. PMID: 24140475 Review.
-
Pathway-based identification of biomarkers for targeted therapeutics: personalized oncology with PI3K pathway inhibitors.Sci Transl Med. 2010 Aug 4;2(43):43ra55. doi: 10.1126/scitranslmed.3001065. Sci Transl Med. 2010. PMID: 20686178
-
Activation of PI3K-Akt signaling pathway promotes prostate cancer cell invasion.Int J Cancer. 2007 Oct 1;121(7):1424-32. doi: 10.1002/ijc.22862. Int J Cancer. 2007. PMID: 17551921
Cited by
-
Enzyme Is the Name-Adapter Is the Game.Cells. 2024 Jul 25;13(15):1249. doi: 10.3390/cells13151249. Cells. 2024. PMID: 39120280 Free PMC article. Review.
-
PQR309, a dual PI3K/mTOR inhibitor, synergizes with gemcitabine by impairing the GSK-3β and STAT3/HSP60 signaling pathways to treat nasopharyngeal carcinoma.Cell Death Dis. 2024 Mar 30;15(3):237. doi: 10.1038/s41419-024-06615-8. Cell Death Dis. 2024. PMID: 38555280 Free PMC article.
-
Design, synthesis, molecular modelling and biological evaluation of novel 6-amino-5-cyano-2-thiopyrimidine derivatives as potent anticancer agents against leukemia and apoptotic inducers.J Enzyme Inhib Med Chem. 2024 Dec;39(1):2304625. doi: 10.1080/14756366.2024.2304625. Epub 2024 Feb 13. J Enzyme Inhib Med Chem. 2024. PMID: 38348824 Free PMC article.
-
K-Ras(V12) differentially affects the three Akt isoforms in lung and pancreatic carcinoma cells and upregulates E-cadherin and NCAM via Akt3.Cell Commun Signal. 2024 Jan 30;22(1):85. doi: 10.1186/s12964-024-01484-2. Cell Commun Signal. 2024. PMID: 38291468 Free PMC article.
-
A combined opposite targeting of p110δ PI3K and RhoA abrogates skin cancer.Commun Biol. 2024 Jan 5;7(1):26. doi: 10.1038/s42003-023-05639-8. Commun Biol. 2024. PMID: 38182748 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous